Q1 2020

Source filing unavailable

Q1 2020 · —

Revenue—

Net Income

-$24.89M

N/M vs Q1 2019

EPS Diluted

-$5.99

no prior Q1 2019 on file

Operating Income-$26,458,000—

Operating Cash Flow-$22,334,000—

Free Cash Flowderived-$23,354,000—

Same quarter

Metric	Q1 2020	Q1 2019
Net Income	-$24.89M	-$14.18M
EPS Diluted	-$5.99	—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR